Standout Papers

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nas... 2017 2026 2020 2023 440
  1. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study (2017)
    Chiun Hsu, Se‐Hoon Lee et al. Journal of Clinical Oncology
  2. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (2017)
    Esma Saâda-Bouzid, Andy Karabajakian et al. Annals of Oncology

Immediate Impact

4 by Nobel laureates 6 from Science/Nature 65 standout
Sub-graph 1 of 20

Citing Papers

Natural killer cell therapies
2024 StandoutNature
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
4 intermediate papers

Works of Caroline Even being referenced

TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma
2018
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
2017 Standout
and 2 more

Author Peers

Author Last Decade Papers Cites
Caroline Even 1706 817 659 795 141 2.4k
G Schwaab 1413 996 1108 690 92 2.9k
Dan P. Zandberg 1289 618 428 409 95 2.1k
Nicole G. Chau 1224 468 758 439 79 2.2k
Glenn J. Hanna 1313 693 489 547 143 2.5k
Yungan Tao 1002 1022 719 631 109 2.2k
Hyunseok Kang 1916 992 970 862 101 3.2k
Ammar Sukari 1458 361 301 615 114 2.2k
Yan‐Qun Xiang 889 834 524 408 94 1.9k
Joonas H. Kauppila 790 427 1248 880 120 2.6k
Antonio López–Pousa 1748 792 847 1908 181 3.5k

All Works

Loading papers...

Rankless by CCL
2026